Dr Bita Fakhri from Stanford University in Stanford, California, discusses recent updates from ASH 2023 for the management of chronic lymphocytic leukemia and Richter’s syndrome.

Dr Andrew M Evens from the Rutgers Cancer Institute of New Jersey in New Brunswick and Dr Sonali M Smith from the University of Chicago in Illinois discuss clinical decision-making with numerous treatment strategies for lymphoma.

Dr Stephen T Oh from Washington University School of Medicine in St Louis, Missouri, discusses current and emerging monitoring and management strategies for myelofibrosis.

Dr Lindsey Roeker from Memorial Sloan Kettering Cancer Center in New York, New York, and Dr Jeff Sharman of the US Oncology Network in Eugene, Oregon, discuss relevant datasets from 2023 on the management of chronic lymphocytic leukemia.

Dr Richard M Stone from Dana-Farber Cancer Institute in Boston discusses the optimal selection and sequencing of systemic therapies for patients with acute myeloid leukemia and myelodysplastic syndromes.

Dr Gail J Roboz from Weill Cornell Medicine in New York discusses the optimal management of acute myeloid leukemia and myelodysplastic syndromes.

Dr Naval Daver from The University of Texas MD Anderson Cancer Center discusses optimizing the management of acute myeloid leukemia and myelodysplastic syndromes. Topics include the productivity of researchers in leukemia, the potential of checkpoint inhibitors, challenges of managing TP53 mutated disease, various drug therapies for AML and MDS, management of qtc prolongation, combination therapy, and the continuation of Van Aza treatment.

Dr Toby A Eyre and Dr Brad S Kahl discuss the management of relapsed/refractory mantle cell lymphoma, including treatment options like BTK inhibitors and CAR T-cell therapy, ongoing clinical trials, toxicity analysis of BTK inhibitors, use of MRD in clinical practice, combination treatment, and side effect management.

Dr Joseph Mikhael discusses updates in multiple myeloma management, including the concept of stopping treatment for patients with deep responses, the use of MRD negativity to determine treatment level, neurological toxicities associated with certain treatments, utilization of specific treatments in medical oncology offices, advantages of bertimide vs. lintalitamide, and the examination of a treatment for multiple myeloma.

Dr Matthew Matasar from the Rutgers Cancer Institute of New Jersey in New York, New York, discusses the current and future role of CD20 x CD3 bispecific antibodies in the management of non-Hodgkin lymphoma.